about
sameAs
A comparison of immunotoxic effects of nanomedicinal products with regulatory immunotoxicity testing requirementsA Micro/Nano Composite for Combination Treatment of Melanoma Lung MetastasisMelanin-Based Contrast Agents for Biomedical Optoacoustic Imaging and Theranostic Applications.An emerging integration between ionic liquids and nanotechnology: general uses and future prospects in drug delivery.Strategies for improving drug delivery: nanocarriers and microenvironmental priming.Spotlight on the delivery of photosensitizers: different approaches for photodynamic-based therapies.Post-nano strategies for drug delivery: Multistage porous silicon microvectors.Multiple Administrations of Viral Nanoparticles Alter in Vivo Behavior-Insights from Intravital Microscopy.A pyruvate decarboxylase-mediated therapeutic strategy for mimicking yeast metabolism in cancer cells.Zinc oxide nanoparticles harness autophagy to induce cell death in lung epithelial cells.Nanomedicinal products: a survey on specific toxicity and side effects.A chloroquine-induced macrophage-preconditioning strategy for improved nanodelivery.Enzyme-responsive multistage vector for drug delivery to tumor tissue.A Liposome Encapsulated Ruthenium Polypyridine Complex as a Theranostic Platform for Triple-Negative Breast Cancer.PMA-Induced THP-1 Macrophage Differentiation is Not Impaired by Citrate-Coated Platinum Nanoparticles.In Search of a Converging Cellular Mechanism in Nanotoxicology and Nanomedicine in the Treatment of Cancer.A Novel DNA Aptamer for Dual Targeting of Polymorphonuclear Myeloid-derived Suppressor Cells and Tumor Cells.Nanomedicine for immunosuppressive therapy: achievements in pre-clinical and clinical research.Progress in Nanomedicine: Approved and Investigational Nanodrugs.Big Potential from Small Agents: Nanoparticles for Imaging-Based Companion Diagnostics.Multi-step encapsulation of chemotherapy and gene silencing agents in functionalized mesoporous silica nanoparticles.Priming the body to receive the therapeutic agent to redefine treatment benefit/risk profile.
P2860
Q26744352-71FB22E8-D5D8-4822-84EC-4EAD7ABC014CQ36813889-11FB76D2-FCDD-43A8-93FD-82E24C5A746BQ38637213-745E36FA-A411-41D6-8416-4C3397BC282DQ38681052-E6860E28-6A79-4F11-9C71-1B58C1503E64Q38968910-9DABFB7A-EFC2-490F-AB0A-BFA497602B9FQ39177662-1C46A06E-C6DC-4389-BAA4-2587E1D0048FQ39410383-16FA346C-016C-44EF-B1F0-2953E59E12D8Q40765081-C21BDE3A-B38E-4892-ADC2-669A5C1E4AE5Q41112245-3EA55590-BB2A-4A09-9438-95AC376E0FEEQ41335567-B60B6DAE-3ED8-49BC-86ED-264F55F5976BQ41545896-575B097E-8F3D-4DB6-B547-65D655D0C632Q42645380-0E85F5EB-AE09-44F0-93B8-8CD9A050D97FQ42695589-A8384D23-97AF-411F-8666-A3A18FAA2CFBQ42972230-03097873-5793-4059-89CB-2E25B9A1A191Q45159306-08B42612-C824-4516-8414-11458CE26D9CQ46828103-66700929-218A-42C4-B482-434801F7A3DBQ47207633-E5453E04-853C-4B7C-9B45-96F434532230Q47771876-9773B40D-1D63-45BD-A683-FFE8C4325C73Q49188363-BF43ACAD-CE24-460B-AC74-D51A8EDF2CECQ50422486-F057D251-E873-49D3-93B1-FEC5BFF7818DQ50921061-F53EA0F2-442D-472E-B267-70E51EB16AA6Q55020915-24426F59-386E-4948-A008-724334AA9414
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Safety of Nanoparticles in Medicine
@ast
Safety of Nanoparticles in Medicine
@en
Safety of Nanoparticles in Medicine
@nl
type
label
Safety of Nanoparticles in Medicine
@ast
Safety of Nanoparticles in Medicine
@en
Safety of Nanoparticles in Medicine
@nl
prefLabel
Safety of Nanoparticles in Medicine
@ast
Safety of Nanoparticles in Medicine
@en
Safety of Nanoparticles in Medicine
@nl
P2093
P2860
P3181
P1433
P1476
Safety of Nanoparticles in Medicine
@en
P2093
Chunying Chen
Donatella Paolino
Emanuela Gentile
Guangjun Nie
Haifa Shen
Jianliang Shen
Massimo Fresta
Mauro Ferrari
P2860
P304
P3181
P356
10.2174/1389450115666140804124808
P407
P50
P577
2015-01-01T00:00:00Z